Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $48000.0.

  • Biodesix's Capital Expenditures fell 7922.08% to $48000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 8117.21%. This contributed to the annual value of $3.2 million for FY2024, which is 8590.69% down from last year.
  • Per Biodesix's latest filing, its Capital Expenditures stood at $48000.0 for Q3 2025, which was down 7922.08% from $51000.0 recorded in Q2 2025.
  • Biodesix's 5-year Capital Expenditures high stood at $7.7 million for Q1 2023, and its period low was $48000.0 during Q3 2025.
  • For the 5-year period, Biodesix's Capital Expenditures averaged around $1.7 million, with its median value being $530000.0 (2021).
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 282977.1% in 2023, then crashed by 9735.2% in 2025.
  • Biodesix's Capital Expenditures (Quarter) stood at $530000.0 in 2021, then surged by 264.15% to $1.9 million in 2022, then surged by 54.61% to $3.0 million in 2023, then plummeted by 71.88% to $839000.0 in 2024, then crashed by 94.28% to $48000.0 in 2025.
  • Its last three reported values are $48000.0 in Q3 2025, $51000.0 for Q2 2025, and $74000.0 during Q1 2025.